Date: 2015-12-11
Type of information: Nomination
Compound:
Company: Crispr Therapeutics (Switzerland - UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 11, 2015, CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, announced the appointment of Tony Coles, M.D., to the company’s Board of Directors. Dr. Coles is the founding investor and serves as Chairman and Chief Executive Officer of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Prior to founding Yumanity, Dr. Coles was Chairman and Chief Executive Officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013 for $10.5 billion. Dr. Coles has previously held various executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Inc., BMS and Merck & Co, Inc. Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School. He earned his M.D. from Duke University, a master’s degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University. Dr. Coles curently serves as a member of the Board of Directors of McKesson Corporation (NYSE: MCK), is Vice Chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. In March 2015, Dr. Coles was named to the NIH working group tasked with charting the course for President Obama’s Precision Medicine Initiative.
Financial terms:
Latest news:
